Clinical laboratory

Soluble receptor of advanced glycation end-products in patients with acute myocardial infarction treated with remote ischaemic conditioning.

PMID 25974999


Several studies have demonstrated that soluble receptor of advanced glycation end-products (sRAGE) is a valuable inflammatory biomarker in cardiovascular disease (CVD). Remote ischaemic conditioning may rescue myocardial tissue during acute myocardial infarction (AMI). In the present study, we evaluate whether sRAGE is a helpful biomarker in patients with AMI receiving remote ischaemic conditioning. Plasma sRAGE levels were measured in 191 patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous intervention (pPCI) of which 97 patients were randomised to receive remote ischaemic conditioning. The sRAGE levels were not different when compared to the randomised controls. In 122 patients, measurement of myocardial salvage index (SI) was obtained. Patients who received remote ischaemic conditioning had significantly higher SI compared to the controls (p < 0.03), although this effect was not seen in sRAGE concentrations. However, sRAGE levels increased with higher New York Heart Association (NYHA) classification after 30 days of follow-up. sRAGE levels do not reflect increased SI in AMI patients who received remote ischaemic conditioning prior to hospital admission.